BRPI0407506A - compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos - Google Patents
compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmosInfo
- Publication number
- BRPI0407506A BRPI0407506A BRPI0407506-4A BRPI0407506A BRPI0407506A BR PI0407506 A BRPI0407506 A BR PI0407506A BR PI0407506 A BRPI0407506 A BR PI0407506A BR PI0407506 A BRPI0407506 A BR PI0407506A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- ring
- alkyl
- treatment
- metabolic disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTOS PARA O TRATAMENTO DE DISTúRBIOS METABóLICOS, SEU USO E COMPOSIçãO FARMACêUTICA COMPREENDENDO OS MESMOS". A presente invenção refere-se a agentes úteis para o tratamento de vários distúrbios metabólicos, tais como síndrome da resistência à insulina, diabetes, hiperlipidemia, doença do fígado gorduroso, caquexia, obesidade, aterosclerose e arteriosclerose. Fórmula (I) em que n é 1 ou 2; m é 0, 1, 2, 4, ou 5; q é 0 ou 1; t é 0 ou 1; R¬ 2¬ é alquila tendo de 1 a 3 átomos de carbono; R¬ 3¬ é hidrogênio, halo, alquila tendo de 1 a 3 átomos de carbono, ou alcóxi tendo de 1 a 3 átomos de carbono; A é fenila, não-substituída ou substituída por 1 ou 2 grupos selecionados de: halo, alquila tendo 1 ou 2 átomos de carbono, perfluorometila, alcóxi tendo 1 ou 2 átomos de carbono, e perfluorometóxi; ou cicloalquila tendo de 3 a 6 átomos de carbono do anel em que a cicloalquila é não-substituída ou um ou dois carbonos do anel são independentemente monossubstituídos por metila ou etila; ou um anel heteroaromático de 5 ou 6 membros tendo 1 ou 2 heteroátomos do anel selecionados de N, S e O e o anel heteroaromático é covalentemente ligado ao resíduo do composto de fórmula (I) por um carbono do anel; e R¬ 1¬ é hidrogênio ou alquila tendo 1 ou 2 átomos de carbono. Alternativamente, quando R¬ 1¬ for hidrogênio, o agente biologicamente ativo pode ser um sal farmaceuticamente aceitável do composto de Fórmula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44716803P | 2003-02-13 | 2003-02-13 | |
PCT/US2004/003718 WO2004073611A2 (en) | 2003-02-13 | 2004-02-09 | Compounds for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0407506A true BRPI0407506A (pt) | 2006-02-14 |
Family
ID=32908414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0407506-4A BRPI0407506A (pt) | 2003-02-13 | 2004-02-09 | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos |
Country Status (19)
Country | Link |
---|---|
US (3) | US7615575B2 (pt) |
EP (2) | EP1601251B1 (pt) |
JP (2) | JP4697962B2 (pt) |
KR (1) | KR101106631B1 (pt) |
CN (1) | CN1750758B (pt) |
AU (2) | AU2004212905B2 (pt) |
BR (1) | BRPI0407506A (pt) |
CA (1) | CA2513092C (pt) |
ES (1) | ES2530235T3 (pt) |
HK (1) | HK1079400A1 (pt) |
IL (1) | IL169332A (pt) |
MX (1) | MXPA05008600A (pt) |
NO (1) | NO334606B1 (pt) |
NZ (1) | NZ542072A (pt) |
PL (1) | PL377712A1 (pt) |
RU (2) | RU2005128501A (pt) |
UA (1) | UA81013C2 (pt) |
WO (1) | WO2004073611A2 (pt) |
ZA (1) | ZA200504558B (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1461323B1 (en) | 2001-06-12 | 2013-10-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
CA2502297C (en) * | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
RU2005128501A (ru) * | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
CA2521621C (en) | 2003-04-15 | 2011-11-01 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
DE602004024382D1 (de) | 2003-04-22 | 2010-01-14 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
WO2004098496A2 (en) * | 2003-04-30 | 2004-11-18 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
RU2349584C2 (ru) * | 2003-08-20 | 2009-03-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических нарушений |
CA2602854C (en) | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
KR20080089453A (ko) | 2006-01-25 | 2008-10-06 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
AU2007208127A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
NZ570334A (en) * | 2006-02-02 | 2011-07-29 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
CA2637884A1 (en) * | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
NZ570100A (en) * | 2006-02-28 | 2011-01-28 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
WO2007117791A2 (en) * | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
MX2008014560A (es) * | 2006-05-18 | 2008-11-28 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de trastornos metabolicos. |
NZ573031A (en) * | 2006-06-09 | 2011-11-25 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
CA2661293A1 (en) * | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
FR2917084B1 (fr) * | 2007-06-05 | 2009-07-17 | Galderma Res & Dev | Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques. |
JP5496913B2 (ja) * | 2008-01-15 | 2014-05-21 | ウェルスタット セラピューティクス コーポレイション | 代謝異常の治療のための化合物 |
UA103894C2 (ru) | 2008-03-13 | 2013-12-10 | Уеллстат Терепьютикс Корпорейшн | Соединения и способ для снижения уровня мочевой кислоты |
AU2013200226B2 (en) * | 2008-03-13 | 2015-01-15 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
WO2011046800A1 (en) * | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
CN102399148B (zh) * | 2010-09-14 | 2014-03-05 | 中国科学院成都生物研究所 | 一类降血脂化合物及其制备方法和用途 |
FR2976943B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
CA2963276A1 (en) * | 2014-10-10 | 2016-04-14 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
US10702488B2 (en) * | 2017-12-19 | 2020-07-07 | Theriac Biomedical Inc. | PPAR-γ activators, HDAC inhibitors and their therapeutical usages |
US11497723B1 (en) * | 2017-12-19 | 2022-11-15 | Tony Antakly | PPAR-gamma activators, HDAC inhibitors and their therapeutical usages |
MA53188A1 (fr) * | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2100341A (en) * | 1934-11-24 | 1937-11-30 | United Shoe Machinery Corp | Shoe bottom coating machine |
GB1393854A (en) * | 1973-02-26 | 1975-05-14 | Pfizer | Benzoic acid compounds and pharmaceutical compositions containing them |
US4067892A (en) | 1973-08-23 | 1978-01-10 | Beecham Group Limited | Substituted (4-carboxyphenoxy) phenyl alkane compounds |
AT338252B (de) * | 1974-01-14 | 1977-08-10 | Isf Spa | Verfahren zur herstellung der neuen 4-cyclopropylmethoxy-3-chlorphenylessigsaure sowie ihrer salze |
CS175831B1 (pt) | 1974-12-17 | 1977-05-31 | ||
GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
US4268442A (en) * | 1978-11-14 | 1981-05-19 | Sagami Chemical Research Center | Process for preparing aromatic acetic acid |
US4663478A (en) | 1984-02-14 | 1987-05-05 | Hidefuni Hirai | Process for producing a para-substituted phenol derivative |
EP0279630B1 (en) | 1987-02-16 | 1993-10-13 | Konica Corporation | Developer for light-sensitive lithographic printing plate capable of processing commonly the negative-type and the positive type and developer composition for light-sensitive material |
JPH0770025B2 (ja) | 1987-09-16 | 1995-07-31 | 富士通株式会社 | 薄膜磁気ヘッドの製造方法 |
US4923501A (en) | 1987-11-04 | 1990-05-08 | Kumiai Chemical Industry Co., Ltd. | Pyrimidine derivatives, processes for their production, and herbicidal method and compositions |
DE3738406A1 (de) * | 1987-11-12 | 1989-05-24 | Henkel Kgaa | Sebosuppressive topische zubereitungen |
JPH01216961A (ja) | 1988-02-25 | 1989-08-30 | Takeda Chem Ind Ltd | 12−リポキシゲネース阻害剤 |
GB8806471D0 (en) * | 1988-03-18 | 1988-04-20 | Tisdale M J | Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours |
US4897397A (en) * | 1988-12-16 | 1990-01-30 | Schering Corporation | Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents |
JPH0348603A (ja) | 1989-07-14 | 1991-03-01 | Wakayama Pref Gov | 抗菌防臭材料 |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
US5589492A (en) * | 1992-04-10 | 1996-12-31 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of Type-II diabetes |
KR950703280A (ko) | 1992-09-09 | 1995-09-20 | 미리암 디.메코너헤이 | 제초성 벤젠 화합물(Herbicidal Benzene Compounds) |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
JPH06293700A (ja) | 1993-04-08 | 1994-10-21 | Nippon Soda Co Ltd | 6−クロロサリチル酸の製造法 |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
JPH07206658A (ja) | 1994-01-12 | 1995-08-08 | Shiseido Co Ltd | 尋常性座瘡治療剤 |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
JPH08119959A (ja) | 1994-10-20 | 1996-05-14 | Oyo Seikagaku Kenkyusho | キサントン誘導体及びこれを有効成分とするモノアミン酸化酵素阻害剤 |
US5728718A (en) | 1994-12-20 | 1998-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same |
US5530157A (en) | 1995-02-16 | 1996-06-25 | Scios Nova Inc. | Anti-inflammatory benzoic acid derivatives |
FR2730731B1 (fr) | 1995-02-20 | 1997-04-04 | Rhone Poulenc Chimie | Procede de carboxylation d'un ether aromatique |
AU4953796A (en) | 1995-03-15 | 1996-10-02 | Sanyko Company, Limited | Dipeptide compounds having ahpba structure |
JPH08325250A (ja) | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規置換フェノール誘導体 |
US5519133A (en) | 1995-06-02 | 1996-05-21 | American Cyanamid Co. | 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents |
US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
AU1698997A (en) | 1996-01-16 | 1997-08-11 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE69716424T2 (de) | 1996-05-24 | 2003-02-20 | Neurosearch A/S, Ballerup | Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker |
US6211215B1 (en) | 1996-07-19 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
JPH1087489A (ja) | 1996-09-13 | 1998-04-07 | Sankyo Co Ltd | Ahpba構造含有ジペプチド化合物を有効成分とする医薬 |
JP2001500864A (ja) | 1996-09-13 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | トロンビン阻害物質 |
JP3981771B2 (ja) | 1996-10-19 | 2007-09-26 | 株式会社クレハ | 2−ベンジルオキシ−6−アルコキシ安息香酸誘導体、その製造方法及び、農園芸用殺菌剤 |
WO1999011255A1 (fr) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
AU732335B2 (en) | 1997-09-09 | 2001-04-12 | Merck & Co., Inc. | 3-(iodophenoxymethyl) carbapenem antibacterials |
US6525042B1 (en) | 1997-09-30 | 2003-02-25 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
AU735737B2 (en) | 1997-10-14 | 2001-07-12 | Asahi Kasei Kabushiki Kaisha | Biphenyl-5-alkanoic acid derivatives and use thereof |
US6384080B1 (en) | 1998-04-20 | 2002-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase |
JP4154773B2 (ja) | 1998-11-13 | 2008-09-24 | 住友電気工業株式会社 | 単結晶製造方法および装置 |
GB9914371D0 (en) | 1999-06-18 | 1999-08-18 | Smithkline Beecham Plc | Novel compounds |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
AUPQ570100A0 (en) * | 2000-02-17 | 2000-03-09 | Fujisawa Pharmaceutical Co., Ltd. | Beta-alanine derivatives and their use as receptor antagonists |
US6632765B1 (en) | 2000-06-23 | 2003-10-14 | Chervon U.S.A. Inc. | Catalyst regeneration via reduction with hydrogen |
MXPA02012708A (es) | 2000-06-28 | 2003-09-22 | Tularik Inc | Moduladores ppar-gamma de quinolinilo y benzotiazolilo. |
AU2001267878A1 (en) | 2000-07-05 | 2002-01-14 | Ajinomoto Co. Inc. | Hypoglycemics |
PE20020347A1 (es) | 2000-08-29 | 2002-05-10 | Abbott Lab | Acidos amino (oxo) aceticos inhibidores de la proteina tirosina fosfatasa |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
EP1461323B1 (en) * | 2001-06-12 | 2013-10-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
DE10135027A1 (de) * | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
ATE420847T1 (de) * | 2002-02-21 | 2009-01-15 | Asahi Kasei Pharma Corp | Substituiertes phenylalkansäurederivat und dessen verwendung |
CA2502297C (en) * | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
DE10257785A1 (de) * | 2002-12-11 | 2004-07-01 | Bayer Healthcare Ag | Isophthalsäurederivate |
WO2004072018A1 (ja) | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
RU2005128501A (ru) | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
JP4282345B2 (ja) | 2003-03-12 | 2009-06-17 | 株式会社日立製作所 | 半導体集積回路装置 |
CA2521621C (en) | 2003-04-15 | 2011-11-01 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
DE602004024382D1 (de) * | 2003-04-22 | 2010-01-14 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
WO2004098496A2 (en) | 2003-04-30 | 2004-11-18 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
MXPA06001739A (es) * | 2003-08-14 | 2006-05-12 | Asahi Kasei Pharma Corp | Derivado de acido arilalcanoico substituido y uso del mismo. |
CA2536089A1 (en) | 2003-08-20 | 2005-03-03 | Eli Lilly And Company | Ppar modulators |
RU2349584C2 (ru) | 2003-08-20 | 2009-03-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических нарушений |
US7541455B2 (en) * | 2003-12-22 | 2009-06-02 | Ventana Medical Systems, Inc. | Microwave mediated synthesis of nucleic acid probes |
CA2602854C (en) | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
UA95613C2 (ru) | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
AU2007208127A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
KR20080089453A (ko) | 2006-01-25 | 2008-10-06 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
NZ570334A (en) | 2006-02-02 | 2011-07-29 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
CA2637884A1 (en) | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
MX2008014560A (es) | 2006-05-18 | 2008-11-28 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de trastornos metabolicos. |
-
2004
- 2004-02-09 RU RU2005128501/15A patent/RU2005128501A/ru not_active Application Discontinuation
- 2004-02-09 NZ NZ542072A patent/NZ542072A/en not_active IP Right Cessation
- 2004-02-09 JP JP2005518490A patent/JP4697962B2/ja not_active Expired - Fee Related
- 2004-02-09 EP EP04709467.7A patent/EP1601251B1/en not_active Expired - Lifetime
- 2004-02-09 CN CN2004800041504A patent/CN1750758B/zh not_active Expired - Fee Related
- 2004-02-09 PL PL377712A patent/PL377712A1/pl unknown
- 2004-02-09 KR KR1020057014896A patent/KR101106631B1/ko not_active IP Right Cessation
- 2004-02-09 ES ES04709467.7T patent/ES2530235T3/es not_active Expired - Lifetime
- 2004-02-09 WO PCT/US2004/003718 patent/WO2004073611A2/en active Application Filing
- 2004-02-09 MX MXPA05008600A patent/MXPA05008600A/es active IP Right Grant
- 2004-02-09 US US10/531,630 patent/US7615575B2/en not_active Expired - Fee Related
- 2004-02-09 BR BRPI0407506-4A patent/BRPI0407506A/pt not_active Application Discontinuation
- 2004-02-09 CA CA2513092A patent/CA2513092C/en not_active Expired - Fee Related
- 2004-02-09 AU AU2004212905A patent/AU2004212905B2/en not_active Ceased
- 2004-02-09 EP EP10184293A patent/EP2266946A3/en not_active Withdrawn
- 2004-09-02 UA UAA200508520A patent/UA81013C2/uk unknown
-
2005
- 2005-06-03 ZA ZA200504558A patent/ZA200504558B/xx unknown
- 2005-06-21 IL IL169332A patent/IL169332A/en not_active IP Right Cessation
- 2005-06-30 NO NO20053211A patent/NO334606B1/no not_active IP Right Cessation
- 2005-12-13 HK HK05111437.3A patent/HK1079400A1/xx not_active IP Right Cessation
-
2007
- 2007-08-20 US US11/841,489 patent/US7605181B2/en not_active Expired - Fee Related
-
2008
- 2008-10-08 AU AU2008229824A patent/AU2008229824A1/en not_active Abandoned
- 2008-12-24 RU RU2008151414/15A patent/RU2521284C2/ru not_active IP Right Cessation
-
2009
- 2009-07-24 JP JP2009173719A patent/JP2009242434A/ja not_active Withdrawn
- 2009-08-31 US US12/550,482 patent/US7932290B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407506A (pt) | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos | |
NO20054791D0 (no) | Forbindelser for behandling av stoffskiftesykdommer | |
HK1083462A1 (en) | Compounds for the treatment of metabolic disorders | |
HK1083460A1 (en) | Compounds for the treatment of metabolic disorders | |
UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
WO2007137008A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2007087505A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
BRPI0413758A (pt) | compostos para o tratamento de transtornos metabólicos | |
NO20064297L (no) | Aminoalkoholforbindelse | |
NO20003399L (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
ATE540675T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
HUT59124A (en) | Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient | |
WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
MA32060B1 (fr) | Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique | |
RU2005124286A (ru) | Производное олигосахаридов | |
WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |